Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Management of Treatment-Resistant Depression in Real -World Clinical Practice Settings Across Asia

Authors
Wang, GangHan, ChangsuLiu, Chia-YihChan, SandraKato, TadafumiTan, WilsonZhang, LiliFeng, YuNg, Chee H.
Issue Date
2020
Publisher
DOVE MEDICAL PRESS LTD
Keywords
Asia; treatment-resistant depression; diagnosis; management
Citation
NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.16, pp.2943 - 2959
Indexed
SCIE
SCOPUS
Journal Title
NEUROPSYCHIATRIC DISEASE AND TREATMENT
Volume
16
Start Page
2943
End Page
2959
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/59085
DOI
10.2147/NDT.S264813
ISSN
1176-6328
Abstract
Purpose: Consensus is lacking on the management of treatment-resistant depression (TRD), resulting in significant variations on how TRD patients are being managed in real-world practice. A survey explored how clinicians managed TRD across Asia, followed by an expert panel that interpreted the survey results and provided recommendations on how TRD could be managed in real-world clinical settings. Methods: Between March and July 2018, 246 clinicians from Hong Kong, Japan, Mainland China, South Korea, and Taiwan completed a survey related to their treatment approaches for TRD. Results: The survey showed physicians using more polytherapy (71%) compared to maintaining patients on monotherapy (29%). The most commonly (23%) administered polytherapy involved antidepressant augmentation with antipsychotics that 19% of physicians also indicated as their most important approach for managing TRD. The highest number of physicians (34%) ranked switching to another class of antidepressants as their most important approach, while 16% and 9% chose antidepressant combinations and electroconvulsive therapy (ECT), respectively. Conclusion: Taking into account the survey results, the expert panel made general recommendations on the management of TRD. TRD partial-responders to antidepressants should be considered for augmentation with second-generation antipsychotics. For non-responders, switching to another class of antidepressants ought to be considered. TRD patients achieving remission with acute treatment should consider continuing their antidepressants for at least another 6 months to prevent relapse. ECT is a treatment consideration for patients with severe depression or persistent symptoms despite multiple adequate trials of antidepressants. Physicians should also consider the response, tolerability and adherence to the current and previous antidepressants, the severity of symptoms, comorbidities, concomitant medications, preferences, and cost when choosing a TRD treatment approach for each individual patient.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Chang su photo

Han, Chang su
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE